@article{ref1,
title="Neuronavigation-guided rTMS for the treatment of depressive patients with suicidal ideation: a double-blind, randomized, sham-controlled trial",
journal="Clinical pharmacology and therapeutics",
year="2020",
author="Pan, Fen and Shen, Zhe and Jiao, JianPing and Chen, Jinkai and Li, Shangda and Lu, Jing and Duan, Jinfeng and Wei, Ning and Shang, Desheng and Hu, Shaohua and Xu, Yi and Huang, Manli",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="During the last decade, the problem of suicide has become more serious in individuals with depression. Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for major depressive disorder (MDD). This study aims to investigate the efficacy of MRI-based neuronavigation-guided daily high-dose rTMS for rapidly improving suicidal ideation in treatment-naive MDD patients. In the present 1-week double-blind study, 42 treatment-naive MDD patients with suicidal ideation were randomly assigned to the treatment of escitalopram oxalate tablets (10 mg/d) in combination with either active (n = 21) or sham (n = 21) rTMS. The TMS coil was positioned over a specified target location (-44, 40, 29) in left dorsolateral prefrontal cortex（DLPFC）based on MRI data. The severity of suicidal ideation was measured by the Beck Scale for Suicide Ideation (BSI). The 24-item Hamilton Depression Rating Scale (HAMD-24) and Montgomery-Asberg Depression Rating Scale (MADRS) were utilized to assess the severity of depression. The Wisconsin Card Sorting Test (WCST), Continuous Performance Test (CPT) and Stroop Color-Word Test (SCWT) were adopted to assess executive function. In contrast to the sham group, the active rTMS group showed a significantly greater BSI score reduction at the third day and the seventh day (p < 0.001). Moreover, the active rTMS group showed a significantly greater HAMD (p < 0.001) and MADRS (p < 0.001) score reduction at the seventh day in comparison with the sham group. The present findings suggested that the neuronavigation-guided high-dose rTMS may be a novel method to rapidly reduce suicidal ideation and mitigate depressive symptom.<br><br>This article is protected by copyright. All rights reserved.<p /> <p>Language: en</p>",
language="en",
issn="0009-9236",
doi="10.1002/cpt.1858",
url="http://dx.doi.org/10.1002/cpt.1858"
}